• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Science: A Fortnightly Journal of Research >Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vsprimaquine in double blind clinical trial
【24h】

Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vsprimaquine in double blind clinical trial

机译：CDRI化合物80/53（Bulaquine）vs Primaquine在双盲临床试验中的比较抗复发疗效

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

One-year follow-up of malaria patients was undertaken to monitor the antirelapse efficacy of CDRI compound 80/53 (Bulaquine), A total of 697 patients of Plasmodium vivax malaria were included in three arm double blind randomized study comparing CDRI 80/53 with placebo and primaquine, Drugs were given once a day for 5 days and the dose for CDRI 80/53 and primaquine was 25 mg and 15 mg, respectively. Thirty-four patients were lost to followup and 663 patients completed one year trial, Two hundred and fourteen patients came back with second episode during the one-year followup period. A detailed analysis revealed that the relapse rate during non-transmission period with placebo in 16 (10.6%) patients was higher than both in primaquine (3.0%) and CDRI 80/53 (4.9%) groups.
机译：对疟疾患者进行了为期一年的随访，以监测CDRI化合物80/53（布拉金）的抗复发疗效。三组双盲随机研究共纳入697例间日疟原虫疟疾患者，将CDRI 80/53与安慰剂和伯氨喹，每天给药一次，持续5天，CDRI 80/53和伯氨喹的剂量分别为25 mg和15 mg。 34名患者失去随访，663名患者完成了为期一年的试验，124名患者在一年的随访期内再次发作。一项详细的分析显示，安慰剂在非传播期的复发率为16（10.6％），高于伯氨喹（3.0％）和CDRI 80/53（4.9％）组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号